Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 12.81 as of 2026-10-06T14:26:41.144Z.
Consensus retrieved: 2026-10-06T12:14:24.966Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:26:41.144Z.
Quote observation: 2026-10-06T14:25:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a1fa914b4487e4ae5c9b7a635cce1df0c30efb2543a97d65c3cd252c667dccf4
Forward PE Ratio (12.81) = Dated Quote Price ($107.82) / Consensus Forward EPS ($8.41)
FORWARD PE RATIO
12.81
SECTOR MEDIAN · HEALTHCARE
19.54
median of 152 covered companies
CURRENT VS SECTOR MEDIAN
-34.44%
vs the sector median at left
Halozyme Therapeutics, Inc.
Market Cap
$12.79B
Forward PE Ratio
12.81
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Halozyme Therapeutics, Inc. (HALO) | $12.79B | 12.81 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.91B | N/A |
| ICON Public Limited Company (ICLR)vs › | $12.64B | 15.58 |
| Corcept Therapeutics Incorporated (CORT)vs › | $12.53B | N/A |
| BrightSpring Health Services, Inc. Common Stock (BTSG)vs › | $12.52B | 35.09 |
| Penumbra, Inc. (PEN)vs › | $12.50B | 67.42 |
| Baxter International Inc. (BAX)vs › | $12.41B | 11.68 |
| Encompass Health Corporation (EHC)vs › | $12.14B | 20.01 |
| Tempus AI, Inc. (TEM)vs › | $13.71B | N/A |
| Ascendis Pharma A/S (ASND)vs › | $13.95B | N/A |
Trailing P/E
32.2
reported TTM EPS
Forward P/E
12.8
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $8.41 implies +151.0% EPS growth vs the reported trailing $3.35.
At the dated quote price of $107.82, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $8.41 | $8.40 – $8.42 | 4 | 12.8x |
| 2027-12-31 | $10.30 | $9.96 – $10.62 | 4 | 10.5x |
| 2028-12-31 | $11.72 | $11.03 – $12.20 | 3 | 9.2x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
